THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA

被引：0
|
作者：
Teschemaker, A. R. [1 ]
Neslusan, C. [1 ]
Sabapathy, S. [2 ]
Yoong, K. [2 ]
Johansen, P. [3 ]
Willis, M. [3 ]
机构：
[1] Janssen Global Serv LLC, Raritan, NJ USA
[2] Janssen Inc, Toronto, ON, Canada
[3] Swedish Inst Hlth Econ, Lund, Sweden
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.365
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB58
引用
收藏
页码：A62 / A63
页数：4
相关论文
共 50 条
  • [21] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
    Tamborlane, William
    Polidori, David
    Di Prospero, Nicolas
    DIABETES, 2017, 66 : A371 - A371
  • [22] Canagliflozin (CANA) Reduces Serum Uric Acid (SUA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Davies, Michael
    Trujillo, Angelina
    Vijapurkar, Ujjwala
    Damara-Ju, C. V.
    Meininger, Gary
    DIABETES, 2014, 63 : A283 - A284
  • [23] Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)
    Gavin, James R., III
    Davies, Melanie J.
    Davies, Michael
    Vija-Purkar, Ujjwala
    Alba, Maria
    DIABETES, 2014, 63 : A285 - A285
  • [24] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) 10MG AND EMPAGLIFLOZIN (EMPA) 25MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Willis, M.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (07) : A607 - A607
  • [25] US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette Gdovin
    Stern, Lee
    Sriprasert, Michelle
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (01) : 20 - 28
  • [26] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [27] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS INSULIN-SECRETAGOGUES (SULPHONYLUREAS) OR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS AN ADD-ON TO METFORMIN IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    VALUE IN HEALTH, 2014, 17 (07) : A346 - A346
  • [28] Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks
    Stenloef, Kaj
    Cefalu, William T.
    Kim, Kyoung-Ah
    Jodar, Esteban
    Alba, Maria
    Edwards, Robert
    Tong, Cindy
    Canovatchel, William
    Meininger, Gary
    DIABETES, 2013, 62 : A303 - A303
  • [29] Long-term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks
    Bode, Bruce
    Stenlof, Kaj
    Harris, Stewart
    Sullivan, Daniel
    Fung, Albert
    Usiskin, Keith
    DIABETES, 2014, 63 : A71 - A71
  • [30] IMPACT OF PATIENT WEIGHT TRAJECTORY ON COST-EFFECTIVENESS OF TREATMENTS OF TYPE 2 DIABETES MELLITUS (T2DM)
    Schroeder, M.
    Willis, M.
    Johansen, P.
    Girod, I
    Neslusan, C.
    Thompson, G.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
12345